Coverage
-
October 01, 2015
A California federal judge has found that Boston Scientific Corp. did not infringe a stent patent asserted against it by cardiologist David Jang, who claimed that the company owed him more than $200 million in royalties, finding that the company was protected by the rarely invoked ensnarement defense.
1 other articles on this case.
View all »